*Search results from clinicaltrials
1
Compound Hits * Development Status/ Approved indications Indications in development Combination partners MSD/ Keytruda (anti- PD-1) 23 Approved/ mMelanoma (2 nd line, USA) RCC, NSCLC, H&N, BC, MM +Cytotoxics +ipilimumab BMS/Ono/ Opdivo (anti- PD-1) 46 Approved/ Unresectabl e melanoma (JP) Squamous cell NSCLC(3 rd line, EU registration) Non-sq NSCLC, mRCC, CML, mCRC, GBM, H&N, NHL, HL, MM, DLBCL +Cytotoxics +ipilimumab (Anti- CTLA4) +bevacizumab +cetuximab +urelumab (Anti- CD137) +Anti-LAG-3 mAb (Anti-LAG-3) +Anti-KIR mAb (Anti- KIR) Roche/ RG7446 (MPDL328 0) (anti- PD-L1) 13 P3 Melanoma, RCC, NSCLC, BC +ipilimumab (anti- CTLA4) +vemurafinib +Avastin +Tarceva +obinutuzumab +cobimetinib *Search results from clinicaltrials.gov RCC(renal cell carcinoma), NSCLC(non-small cell lung cancer, H&N(head &neck), BC(bladder cancer), MM (multiple myeloma), CML(chronic myeloid leukemia), GBM(Glioblastoma Multiforme), NHL (non- Hodgkin lymphoma), HL (Hodgkin lymphoma), DLBCL(diffuse large B cell lymphoma) Anti-PD-1/PD-L1 Pipeline Comparison
description
Anti-PD-1/PD-L1 Pipeline Comparison. *Search results from clinicaltrials.gov - PowerPoint PPT Presentation
Transcript of *Search results from clinicaltrials
Compound Hits * Development Status/Approved indications
Indications in development Combination partners
MSD/Keytruda
(anti-PD-1)
23 Approved/mMelanoma (2nd line, USA)
RCC, NSCLC, H&N, BC, MM +Cytotoxics+ipilimumab
BMS/Ono/Opdivo
(anti-PD-1)
46 Approved/Unresectable melanoma (JP)
Squamous cell NSCLC(3rd line, EU registration)Non-sq NSCLC, mRCC, CML, mCRC, GBM, H&N, NHL, HL, MM, DLBCL
+Cytotoxics+ipilimumab (Anti-CTLA4)+bevacizumab+cetuximab+urelumab (Anti-CD137)+Anti-LAG-3 mAb (Anti-LAG-3)+Anti-KIR mAb (Anti-KIR)
Roche/RG7446
(MPDL3280)(anti-PD-L1)
13 P3 Melanoma, RCC, NSCLC, BC +ipilimumab (anti-CTLA4)+vemurafinib+Avastin+Tarceva+obinutuzumab+cobimetinib
AstraZeneca/MEDI4736
(anti-PD-L1)
17 P3 Melanoma, mNSCLC, H&N, CRC,
+anti-PD-1 mAb (MEDI0680)+tremelimumab(Anti-CTLA4)+EGFR Tkietc
*Search results from clinicaltrials.govRCC(renal cell carcinoma), NSCLC(non-small cell lung cancer, H&N(head &neck), BC(bladder cancer), MM (multiple myeloma), CML(chronic myeloid leukemia), GBM(Glioblastoma Multiforme), NHL (non-Hodgkin lymphoma), HL (Hodgkin lymphoma), DLBCL(diffuse large B cell lymphoma)
Anti-PD-1/PD-L1 Pipeline Comparison
